Follow
This makes sense - PD1/PDL1 are great targets, but the degree of dominance over the last decade was worrisome. Great to see more diversity
"Our current analysis of global IO clinical trials shows that the field took a turn in 2022 with respect to previous years. After more than a decade of an upward trajectory, we notice a decrease in new clinical trials, a shift driven largely by the reduction in phase II studies using anti-PD1/PDL1 mAbs."
#immunology #immunotherapy #immunooncology
